<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Phil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Newby, L. Kristin</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Early Routine Eptifibatide Use is Not Superior to Delayed Provisional Use in NSTE ACS</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2009</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2009-05-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-20</style></pages><abstract><style  face="normal" font="default" size="100%">The early routine administration of eptifibatide is not superior to delayed provisional eptifibatide use among invasively managed patients with high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS), according to findings from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndromes [EARLY-ACS; NCT00089895] study. Moreover, compared with delayed use, early eptifibatide use increases bleeding and transfusion rates.</style></abstract><number><style face="normal" font="default" size="100%">2</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>